Diabetes Drug May Slow Parkinson’s Disease
Exenatide has shown neuroprotective effects in several animal models of Parkinson’s disease. And in a pilot study of patients with moderately advanced Parkinson’s disease, exenatide was associated with improvements in motor and cognitive function over 12 months (J Parkinsons Dis. 2014;4:337-344).
The current trial enrolled 62 patients with idiopathic Parkinson’s disease who had wearing-off motor fluctuations on dopaminergic therapy and were at Hoehn and Yahr stage 2.5 or less when receiving treatment.
Participants were randomly allocated to subcutaneous injections of exenatide 2 mg (n = 32) or placebo (n = 30) once weekly for 48 weeks in addition to their regular medication, followed by a 12-week washout period.